The bispecific innate cell engager AFM28 eliminates CD123<sup>+</sup> leukemic stem and progenitor cells in AML and MDS.

Finally, when comparing the efficacy of AFM28 to that of the Fc-enhanced anti‐CD123 IgG1, there was a significant trend for superior AML blast reduction by AFM28 in comparison to the Fc-enhanced anti‐CD123 IgG1, in particular towards leukemic blasts with high CD64 expression (Fig. 2E–H and Supplementary Fig. 2E ).

also in 9,775 other papers